Innate Pharma has dosed the first patient in a Phase I trial of its antibody-drug conjugate (ADC), IPH4502, which is designed to target tumours expressing Nectin-4. The Marseille, France-based company ...

Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation PR Newswire SHANGHAI, Jan. 9, 2025 ...

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Nectin-4-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about ...

“ In this study, we aimed to determine the rate of Nectin-4 positivity in a contemporary cohort of HNSCC and to correlate these findings with clinico-pathological parameters.” Nectin-4 has been ...

First-in-class antibody-drug conjugate (ADC) that targets Nectin-4, which is a cell surface protein highly expressed in bladder cancer. Preclinical data suggest that the anticancer activity of it is ...

SAN DIEGO, May 6, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life ...

Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 positive study participants with mUC and cervical cancer ...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will host an event for institutional investors and analysts ...

Combination cohort initiated following successful review of monotherapy cohort Over 100 participants dosed to-date in monotherapy cohort Priority are Head and Neck Squamous Cell Carcinoma (HNSCC) and ...

A systematic literature review was performed on March 2023 using PubMed, MEDLINE, and Embase databases according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.